WILMINGTON, Del., Nov. 12 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE:
AZN) has announced the appointment of Kenneth L. Murtha as Regional Supply
VP- The Americas, effective January 1, 2008. In his new expanded role,
Murtha will oversee distribution in Latin America and supply sites in
Argentina, Brazil, Puerto Rico and Mexico in addition to his North American
responsibilities.
As one of three Regional Supply VPs, Murtha will serve on AstraZeneca's
worldwide Operations leadership team that is driving the Operations
strategy to enable a step change in productivity and optimize its
end-to-end supply chain.
David Smith, EVP of Global Operations comments, "There is great
opportunity for our global supply chain to drive additional value for
patients and contribute to future top-line growth." He added, "Ken's
background and expertise make him the ideal person to deliver on
AstraZeneca's promise to utilize our supply chain as a competitive lever
connecting product packaging in a much more meaningful way with the
patient."
"AstraZeneca is widely recognized for its leadership and innovation in
providing superior customer service. Finding new, effective ways to deliver
value today will be used to create new medicines for patients tomorrow,"
explained Murtha.
Murtha most recently held the position of Vice President, Business
Operations for the U.S. and served as a member of AstraZeneca's U.S.
leadership team. He has worked for the company since 1982, progressing into
ever-expanding roles and responsibilities within the Operations Group. He
obtained a bachelor's degree in pharmacy from the University of Pittsburgh
in 1982 and is a licensed pharmacist in Pennsylvania. He is a board member
of the University of the Sciences in Philadelphia, the International
Leadership Forum for the International Society of Pharmaceutical
Engineering (ISPE), Red Cross of Delmarva and Delaware State Chamber of
Commerce.
About AstraZeneca
AstraZeneca is a major international healthcare business engaged in the
research, development, manufacture and marketing of prescription
pharmaceuticals and the supply of healthcare services. It is one of the
world's leading pharmaceutical companies with healthcare sales of $26.47
billion and leading positions in sales of gastrointestinal, cardiovascular,
neuroscience, respiratory, oncology and infection products. AstraZeneca is
listed in the Dow Jones Sustainability Index (Global) as well as the
FTSE4Good Index.
In the United States, AstraZeneca is a $12.44 billion healthcare
business with more than 12,000 employees. For nearly three decades,
AstraZeneca has offered drug assistance programs side by side with its
medicines, and over the past five years, has provided over $3 billion in
savings to more than 1 million patients throughout the US and Puerto Rico.
AstraZeneca has been named one of the "100 Best Companies for Working
Mothers" by Working Mother magazine and is the only large pharmaceutical
company named to FORTUNE magazine's 2007 list of "100 Best Companies to
Work For." In 2006, for the fifth consecutive year, Science magazine named
AstraZeneca a "Top Employer" on its ranking of the world's most respected
biopharmaceutical employers. For more information about AstraZeneca, please
visit: http://www.astrazeneca-us.com
SOURCE AstraZeneca
 back to top
Related links:
http://www.astrazeneca-us.com
http://www.prnewswire.com/comp/985887.html/
CONTACT:
Kate Klemas of AstraZeneca, +1-302-885-4642,
Kate.Klemas@astrazeneca.com
|
